Lauri Welles

1.7k total citations
19 papers, 1.3k citations indexed

About

Lauri Welles is a scholar working on Oncology, Pathology and Forensic Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Lauri Welles has authored 19 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Lauri Welles's work include Cancer Treatment and Pharmacology (10 papers), Chemotherapy-induced cardiotoxicity and mitigation (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Lauri Welles is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Chemotherapy-induced cardiotoxicity and mitigation (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Lauri Welles collaborates with scholars based in United States, Canada and France. Lauri Welles's co-authors include Gerald Batist, N. Azarnia, Eric P. Winer, Robert J. Belt, Lyndsay N. Harris, Rudolph M. Navari, Philip Chaikin, Christine E. Swenson, Robert Yarchoan and James M. Pluda and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Analytical Biochemistry.

In The Last Decade

Lauri Welles

19 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lauri Welles United States	12	735	288	283	263	262	19	1.3k
Martina Rudelius Germany	24	594 0.8×	177 0.6×	156 0.6×	158 0.6×	595 2.3×	43	1.8k
Rut Isacson Israel	10	1.3k 1.8×	296 1.0×	190 0.7×	130 0.5×	378 1.4×	22	1.9k
Susan Jeffers United States	18	820 1.1×	535 1.9×	128 0.5×	297 1.1×	443 1.7×	32	2.0k
G. Stehle Germany	21	698 0.9×	296 1.0×	47 0.2×	209 0.8×	788 3.0×	53	2.0k
Nely Wigler Israel	10	870 1.2×	645 2.2×	91 0.3×	250 1.0×	424 1.6×	17	1.9k
J Wernz United States	20	1.6k 2.2×	128 0.4×	840 3.0×	398 1.5×	363 1.4×	28	2.3k
Daphne M. Glass United Kingdom	13	522 0.7×	298 1.0×	277 1.0×	30 0.1×	203 0.8×	30	1.3k
Margaret Tonda United States	16	370 0.5×	358 1.2×	110 0.4×	34 0.1×	339 1.3×	45	1.3k
Lawrence D. Kaplan United States	8	459 0.6×	152 0.5×	288 1.0×	47 0.2×	123 0.5×	9	776
Hani M. Babiker United States	18	670 0.9×	65 0.2×	131 0.5×	78 0.3×	361 1.4×	154	1.5k

Countries citing papers authored by Lauri Welles

Since Specialization

Citations

This map shows the geographic impact of Lauri Welles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lauri Welles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lauri Welles more than expected).

Fields of papers citing papers by Lauri Welles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lauri Welles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lauri Welles. The network helps show where Lauri Welles may publish in the future.

Co-authorship network of co-authors of Lauri Welles

This figure shows the co-authorship network connecting the top 25 collaborators of Lauri Welles. A scholar is included among the top collaborators of Lauri Welles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lauri Welles. Lauri Welles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Theodoulou, Maria, Gerald Batist, Susana M. Campos, et al.. (2009). Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive Breast Cancer. Clinical Breast Cancer. 9(2). 101–107. 11 indexed citations

Tulpule, Anil, Byron M. Espina, Nancy E.J. Berman, et al.. (2006). Phase I/II Trial of Nonpegylated Liposomal Doxorubicin, Cyclophosphamide, Vincristine, and Prednisone in the Treatment of Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma. Clinical Lymphoma & Myeloma. 7(1). 59–64. 19 indexed citations

Hochster, H. S., Lauri Welles, Ramesh K. Ramanathan, et al.. (2005). Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. Journal of Clinical Oncology. 23(16_suppl). 3515–3515. 40 indexed citations

Welles, Lauri, H. S. Hochster, R. K. Ramanathan, et al.. (2004). Preliminary results of a randomized study of the safety and tolerability of three oxaliplatin-based regimens as first-line treatment for advanced colorectal cancer (CRC) (“Tree” study). Journal of Clinical Oncology. 22(14_suppl). 3537–3537. 4 indexed citations

Welles, Lauri, Howard S. Höchster, R. K. Ramanathan, et al.. (2004). Preliminary results of a randomized study of the safety and tolerability of three oxaliplatin-based regimens as first-line treatment for advanced colorectal cancer (CRC) (“Tree” study). Journal of Clinical Oncology. 22(14_suppl). 3537–3537. 9 indexed citations

Levine, Alexandra M., Anil Tulpule, Byron M. Espina, et al.. (2004). Liposome-Encapsulated Doxorubicin in Combination With Standard Agents (cyclophosphamide, vincristine, prednisone) in Patients With Newly Diagnosed AIDS-Related Non-Hodgkin's Lymphoma: Results of Therapy and Correlates of Response. Journal of Clinical Oncology. 22(13). 2662–2670. 60 indexed citations

Swenson, Christine E., Lois E. Bolcsak, Gerald Batist, et al.. (2003). Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anti-Cancer Drugs. 14(3). 239–246. 83 indexed citations

Batist, Gerald, Jeremy Barton, Philip Chaikin, Christine E. Swenson, & Lauri Welles. (2002). Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opinion on Pharmacotherapy. 3(12). 1739–1751. 133 indexed citations

Little, Richard F., Katherine Staskus, Denise Whitby, et al.. (2002). A Pilot Study of Cidofovir in Patients with Kaposi Sarcoma. The Journal of Infectious Diseases. 187(1). 149–153. 61 indexed citations

10.

Harris, Lyndsay N., Gerald Batist, Robert J. Belt, et al.. (2001). Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma. Cancer. 94(1). 25–36. 387 indexed citations

11.

Kelley, James A., Heping Zhang, Mark F. Kavlick, et al.. (2001). Fluorometric Determination of 2′-β-Fluoro-2′,3′-dideoxyadenosine 5′-Triphosphate, the Active Metabolite of a New Anti-Human Immunodeficiency Virus Drug, in Human Lymphocytes. Analytical Biochemistry. 288(1). 52–61. 6 indexed citations

12.

Espina, Byron M., et al.. (2001). A phase I/II trial of liposomal doxorubicin (tlc-d99, myocet) in combination with cyclophosphamide, vincristine, and prednisone (comp) for newly diagnosed intermediate and high grade non-Hodgkin's lymphoma (nhl). European Journal of Cancer. 37. S91–S91. 2 indexed citations

13.

Williams, Grant, Patricia Cortazar, Richard Pazdur, Gerald Batist, & Lauri Welles. (2001). Developing Drugs to Decrease the Toxicity of Chemotherapy. Journal of Clinical Oncology. 19(14). 3439–3441. 74 indexed citations

14.

Campos-Gómez, Saúl, et al.. (2001). Cardiac safety and efficacy of TLC D99 (D99) and trastuzumab in patients with advanced breast cancer. European Journal of Cancer. 37. S195–S195. 2 indexed citations

15.

Little, Richard F., Kathleen M. Wyvill, James M. Pluda, et al.. (2000). Activity of Thalidomide in AIDS-Related Kaposi’s Sarcoma. Journal of Clinical Oncology. 18(13). 2593–2602. 223 indexed citations

16.

Shapiro, Charles L., et al.. (1999). Phase II Trial of High-Dose Liposome-Encapsulated Doxorubicin With Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer. Journal of Clinical Oncology. 17(5). 1435–1435. 51 indexed citations

17.

Welles, Lauri, M. Wayne Saville, Jill Lietzau, et al.. (1998). Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.. Journal of Clinical Oncology. 16(3). 1112–1121. 127 indexed citations

18.

Little, Richard F., Lauri Welles, Kathleen M. Wyvill, et al.. (1998). Preliminary results of a phase II study of oral thalidomide in patients with AIDS-related Kaposl's sarcoma (KS). Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 17(4). A16–A16. 4 indexed citations

19.

Welles, Lauri, Richard F. Little, Kathleen M. Wyvill, et al.. (1997). PRELIMINARY RESULTS OF A PHASE II STUDY OF ORAL THALIDOMIDE IN PATIENTS WITH HIV INFECTION AND KAPOSI'S SARCOMA (KS). Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 14(4). A21–A21. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact